FDA Brief

Warning letters Drugs

FDA warning letter to

Allay Pharmaceuticals, LLC

High riskIssued Jan 27, 2021Posted Feb 9, 2021Division of Pharmaceutical Quality Operations II

FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.

What happened

FDA inspected Allay's drug manufacturing facility in Hialeah, Florida, from May 5 to 15, 2020. The agency found inadequate process validation and sub-potent tablet samples, incomplete out-of-specification investigations and inappropriate assay specifications, inadequate stability testing, and quality-unit oversight failures. FDA also determined the firm distributes a tablet biological product without FDA approval or a valid biologics license.

What FDA found

  1. The company failed to adequately validate tablet manufacturing, and FDA found sub-potent samples and one content-uniformity failure.

    21 CFR 211.100(a)
  2. The company did not thoroughly investigate out-of-specification results and set assay specifications looser than the USP standard, missing 13 lots that exceeded its revised specification.

    21 CFR 211.192
  3. The company's stability program was inadequate because long-term stability data were missing for validation batches using a new API supplier, and disintegration testing was not consistently done.

    21 CFR 211.166(a)
  4. The quality control unit failed to oversee API supplier qualification, laboratory computer controls, and complaint handling.

    21 CFR 211.22
  5. The company distributed a (b)(4) tablet biological product without FDA approval or a valid biologics license.

What FDA wants

FDA tells Allay to correct the violations promptly, respond in writing within 15 working days, and provide detailed plans for process validation, investigations, stability, supplier qualification, quality-unit remediation, and testing of lots within expiry. FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • companies that contract with Allay to make finished drug products
  • product owners and distributors of the affected tablets or biological product
  • quality teams overseeing API supplier qualification and stability programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk